- Previous Close
0.0236 - Open
0.0228 - Bid 0.0350 x --
- Ask 0.0508 x --
- Day's Range
0.0228 - 0.0228 - 52 Week Range
0.0166 - 0.0516 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
8.035M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
www.arocell.com22
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 80R.F
View MorePerformance Overview: 80R.F
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 80R.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 80R.F
View MoreValuation Measures
Market Cap
8.20M
Enterprise Value
4.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.22
Price/Book (mrq)
0.48
Enterprise Value/Revenue
0.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-98.04%
Return on Assets (ttm)
-19.25%
Return on Equity (ttm)
-32.55%
Revenue (ttm)
51.58M
Net Income Avi to Common (ttm)
-50.57M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
44.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
11.71M